Study shows alphaHGA is orally bioavailable
Tripep, the Swedish biotechnology company focusing on HIV therapy, has reported that following a microdosing study performed by Pharmaceutical Profiles in Nottingham, UK, alphaHGA is orally bioavailable in humans. Moreover, the study also showed that alphaHGA has good kinetic properties.
Tripep, the Swedish biotechnology company focusing on HIV therapy, has reported that following a microdosing study performed by Pharmaceutical Profiles in Nottingham, UK, alphaHGA is orally bioavailable in humans. Moreover, the study also showed that alphaHGA has good kinetic properties.
AlphaHGA is a new candidate drug against HIV, which has a totally new mode of action as it is the first substance in an entirely new class of compounds against HIV.
In collaboration with Pharmaceutical Profiles (a Clinical Research Organisation based in Nottingham, UK), Tripep has tested the oral bioavailability and plasma pharmacokinetics on human volunteers using 14C labelled alphaHGA. The results showed that alphaHGA was quickly and completely absorbed into the blood after oral administration. The terminal half-life in plasma was approximately 10 hours. The main route of elimination was by urine.
Professor Anders Vahlne, acting ceo and head of research at Tripep, commented: 'These results are very encouraging for the future drug development work on alphaHGA. Phase I/II studies in HIV infected individuals are expected to start later this year or early next year, following successful completion of safety studies in animals.'